Novo Nordisk scraps Type 1 diabetes drug after phase 2 trial

Novo Nordisk has scrapped (PDF) development of anti-IL-21 antibody NN9828 in combination with Victoza after getting a look at phase 2 data in Type 1 diabetics. The news is another setback for a drug that has underwhelmed in multiple indications over the past decade.